New York State Teachers Retirement System Sells 1,000 Shares of Azenta, Inc. (NASDAQ:AZTA)

New York State Teachers Retirement System decreased its position in Azenta, Inc. (NASDAQ:AZTA) by 1.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,165 shares of the company’s stock after selling 1,000 shares during the quarter. New York State Teachers Retirement System owned about 0.13% of Azenta worth $3,302,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in AZTA. Hantz Financial Services Inc. bought a new stake in shares of Azenta in the 2nd quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Azenta in the 1st quarter valued at approximately $49,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Azenta by 150.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after buying an additional 955 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Azenta in the 1st quarter valued at approximately $130,000. Finally, Acadian Asset Management LLC grew its stake in shares of Azenta by 24.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock valued at $143,000 after buying an additional 471 shares in the last quarter. Institutional investors own 99.08% of the company’s stock.

Azenta Stock Up 0.8 %

Shares of AZTA stock opened at $46.52 on Thursday. Azenta, Inc. has a 12 month low of $40.24 and a 12 month high of $69.16. The firm has a market cap of $2.28 billion, a PE ratio of -16.43 and a beta of 1.48. The stock has a 50 day moving average of $46.16 and a 200-day moving average of $50.85.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.09. Azenta had a positive return on equity of 0.89% and a negative net margin of 23.66%. The company had revenue of $173.00 million during the quarter, compared to analyst estimates of $166.14 million. During the same period in the previous year, the company earned $0.13 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, equities analysts predict that Azenta, Inc. will post 0.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AZTA. Needham & Company LLC restated a “buy” rating and issued a $69.00 target price on shares of Azenta in a report on Wednesday, August 7th. Evercore ISI reduced their target price on Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $66.40.

Insider Transactions at Azenta

In other news, CFO Herman Cueto sold 1,595 shares of the company’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60. Following the completion of the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at $1,074,702.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.77% of the company’s stock.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.